Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Monopar Therapeutics (MNPR)

Monopar Therapeutics gets FDA Rare Pediatric Disease designation for ALXN1840 for Wilson disease

Neutral Impact 2 of 5 legal/regulatory Written later

Monopar Therapeutics said the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to ALXN1840 (tiomolibdate choline), its late-stage candidate for Wilson disease. The designation gives the company the potential to receive a pediatric Priority Review Voucher if the drug is approved, but the filing does not say whether approval will come or whether a voucher will be awarded.

Key points

  • FDA granted Rare Pediatric Disease designation to ALXN1840 for Wilson disease, announced June 30, 2026
  • The designation provides potential eligibility for a pediatric Priority Review Voucher at the time of NDA approval
  • The filing does not report revenue, earnings, or guidance

The filing

CompanyMonopar Therapeutics (MNPR)
Form8-K, current report
Filed with the SECJun 30, 2026, 8:00 AM ET
Accession number0001437749-26-022086

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.